Halozyme Therapeutics, Inc. · NASDAQ:HALO

Connaughton Bernadette sold 1,625 Halozyme Therapeutics, Inc. shares (Form 4)

Traded Jul 1, 2026 · Filed Jul 2, 2026

On Jul 1, 2026, Connaughton Bernadette (Director) sold 1,625 Halozyme Therapeutics, Inc. shares at an average US$76.71 for US$125K under a trading plan, leaving 42,044 shares. Filed Jul 2, 2026 (Form 4).

Sold
1,625 shares
Price
US$76.71 average (US$76.40 to US$77.21)
Value
US$125K
Holding after
42,044 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jul 1, 2026Common StockSale1,000US$76.4042,669Direct
Jul 1, 2026Common StockSale625US$77.2142,044Direct

Source

View original at SEC

Related